-Ends- Enquiries: OXB: Sophia Bolhassan, Head of Investor Relations – T: +44 (0) 1865 509 737 / E: ir@oxb.com Oxford, UK – 11 June 2025: OXB (LSE: OXB) ("the Company"), a global quality and innovation-led cell and gene therapy CDMO, provides an update to coincide with its Annual General Meeting being held at 3pm BST today at Windrush Court, Oxford, UK. OXB has demonstrated strong commercial momentum and made good operational and commercial progress in the year 2025 to date, as it continues to provide viral ...

Summary of Sana Biotechnology (SANA) FY Conference Call - June 10, 2025 Company Overview - **Company**: Sana Biotechnology (SANA) - **Industry**: Biotechnology - **Focus**: Development of cell-based therapies, particularly for type one diabetes and CAR T cell therapies Key Points and Arguments Portfolio Strategy and Pipeline - The company is focused on using cells as medicines, specifically through two technologies: hypoimmune technology and in vivo gene modification [3][4] - The majority of capital is allocated towards the hypoimmune platform, which aims to hide cells from immune system recognition, particularly in type one diabetes [5][12] - Type one diabetes affects approximately 9 million people globally, with about 2 million in the U.S., and has seen little meaningful progress in treatment over the past century [6][7] - The goal is to provide a single treatment that results in normal blood sugar levels for life without the need for insulin or immunosuppression [8][12] Type One Diabetes Program - The lead program, SC451, is a hypoimmune iPSC-derived islet cell therapy expected to file an IND in 2026 [15] - Investigator-sponsored trials have shown promising results, including a patient making insulin without immunosuppression for over 35 years [21][22] - The therapy aims to be scalable and consistent, addressing the limitations of current treatments that require lifelong immunosuppression [24][53] Risks and Challenges - Major risks identified include capital and time constraints, safety concerns, and the need for scalable manufacturing [56][57] - The company is focused on ensuring product purity to avoid tumor emergence, which is critical for long-term patient safety [56] CAR T Cell Programs - The company is also developing allogeneic CAR T therapies for oncology and autoimmune diseases, facing competition and investor fatigue in the CAR T space [9][10][11] - The allogeneic CAR T program aims to provide off-the-shelf therapies that do not require patient-specific modifications [61][64] - The company is optimistic about achieving deep B cell depletion in autoimmune settings based on oncology data [62][64] Competitive Landscape - The company differentiates itself by eliminating the need for immunosuppression in its therapies, which is a significant advantage over competitors [52][53] - The market for type one diabetes treatments is vast, with potential for significant revenue if successful [51] Financial Strategy and Partnerships - The company acknowledges the need for additional funding to support its various programs and is exploring partnerships as a non-dilutive option [74][75] - There is a strong commitment to protect the type one diabetes franchise while seeking capital for other programs [75][76] Upcoming Data and Expectations - The company plans to present updated data at the American Diabetes Association meeting, with expectations for stable C peptide levels and glucose-sensitive insulin secretion [35][36] - The focus remains on ensuring that the therapy meets safety and efficacy standards before moving forward with broader applications [66][67] Additional Important Content - The company has made significant progress in developing a master iPSC cell bank, which is crucial for scaling production [41][49] - The challenges of scaling production to meet the needs of millions of patients are acknowledged, with ongoing efforts to ensure genomic stability [46][47] This summary encapsulates the key points discussed during the conference call, highlighting Sana Biotechnology's strategic focus, challenges, and future expectations in the biotechnology sector.

Summary of Abeona Therapeutics (ABEO) Conference Call Company Overview - Abeona Therapeutics is a commercial stage cell and gene therapy company that recently received approval for ZivaSkin, a therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB) [5][70] - The company has a market cap of approximately $300 million and anticipates becoming profitable in the early half of 2026 [6][71] Key Developments - ZivaSkin was approved just over a month ago, and the company has entered into a sale agreement for a Priority Review Voucher (PRV) for $155 million [5][70] - Abeona is funded for eight quarters of operations without accounting for revenue generation [6][71] Launch Metrics and Treatment Centers - Lurie Children's Hospital has been activated as the first qualified treatment center for ZivaSkin [7][72] - The company is tracking patient throughput and referral volume from other centers of excellence [7][72] - The timeline to fully activate all five treatment centers is by the end of 2025 [9][74] Patient Demand and Treatment Capacity - There are currently an upper double-digit number of patients eligible for treatment across the five centers [11][73] - The company expects to treat 10 to 14 patients this year, with the capacity to ramp up to 10 patients per month by the first half of 2026 [18][37] - The treatment window runs from August to November, with minimal disruption expected due to a planned December manufacturing shutdown [20][21] Pricing and Payer Engagement - ZivaSkin is priced at $3.1 million, which is considered reasonable compared to the standard of care costs [28][30] - The company has not faced pushback from payers and has entered agreements covering over 100 million commercially insured lives [31][36] Financial Outlook - Abeona expects to achieve cash flow positivity in 2026 with a target of treating 36 patients [37][39] - The company is confident in exceeding this target, potentially treating up to 50 patients [38][39] Future Plans and Market Expansion - Abeona is exploring regulatory submissions outside the U.S. and assessing reimbursement scenarios in major markets like Western Europe and Japan [46][47] - The company has identified approximately 750 patients in the U.S. with RDEB, with a significant opportunity for repeat treatments [49][51] Competitive Landscape - ZivaSkin differentiates itself by providing long-lasting wound coverage with a single application, addressing both wound healing and quality of life improvements [53][54] Partner Programs - Abeona is eligible for royalties and milestones from partnered programs with Ultragenyx and Atacea, which are not factored into current projections [55][58] Key Milestones Ahead - The company aims to achieve its treatment goals for ZivaSkin and activate additional qualified treatment centers, with several PDUFA action dates for partnered programs expected in 2025 [66][67]

Bio-Techne’s (TECH) GMP reagents, including GMP proteins and small molecules, remain a cornerstone of its cell therapy offering. Acquisitions have continued to play an important role in the company’s efforts to expand its portfolio, as well as enter adjacent markets. Further, the company has begun to pursue clinical diagnostic opportunities on Ella, its automated multiplexing immunoassay instrument platform. However, ongoing macroeconomic volatilities and a challenging research landscape may adversely weigh ...

Core Insights - Abeona Therapeutics has received FDA approval for ZEVASKYN™, the first autologous cell-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB) [1][5] - The company is transitioning to a commercial-stage entity with the launch of ZEVASKYN and has activated its first treatment center [2][4] Recent Developments - ZEVASKYN's FDA approval marks a significant milestone for RDEB patients, with the first treatment expected in Q3 2025 [5] - Abeona has secured a $155 million non-dilutive capital through the sale of its Rare Pediatric Disease Priority Review Voucher (PRV), which will fund operations for over two years [3] - The company has entered into value-based agreements with commercial payer groups, ensuring access to ZEVASKYN for approximately 100 million commercially-insured lives [5] Financial Results - As of March 31, 2025, the company reported cash and cash equivalents totaling $84.5 million, down from $98.1 million at the end of 2024 [6] - Research and development expenses increased to $9.9 million in Q1 2025 from $7.2 million in Q1 2024, primarily due to scaling up manufacturing for ZEVASKYN [7] - The net loss for Q1 2025 was $12.0 million, a significant reduction from a net loss of $31.6 million in Q1 2024 [8][14]

Core Insights - BioLife Solutions, Inc. is a prominent developer and supplier of bioproduction products and services specifically for the cell and gene therapy (CGT) market [1] - The company is actively participating in several upcoming investor conferences, indicating a focus on investor relations and market engagement [3] Company Overview - BioLife Solutions specializes in solutions that preserve the health and functionality of biological materials throughout their lifecycle, including collection, development, storage, and distribution [1] Upcoming Investor Conferences - The company will participate in the following conferences: - 22nd Annual Craig-Hallum Institutional Investor Conference on May 28, 2025, in Minneapolis, MN [3] - Benchmark 2025 Healthcare House Call Virtual Conference on May 29, 2025, virtually [3] - Jefferies Global Life Sciences Conference from June 3 to June 5, 2025, in New York, NY [3] - Wolfe Research Small & Mid-Cap Conference on June 5, 2025, in New York, NY [3] - Northland Growth Conference 2025 on June 25, 2025, virtually [3]

Clearpoint Neuro (CLPT) Q1 2025 Earnings Call May 13, 2025 04:30 PM ET Company Participants Joseph Burnett - President and Chief Executive OfficerDanilo D’Alessandro - CFOMathew Blackman - Managing Director Conference Call Participants Frank Takkinen - Senior Research AnalystAnderson Schock - Research Analyst Operator Please note this conference is being recorded. Comments made on this call may include statements that are forward looking within the meaning of securities laws. These forward looking statement ...

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $8.5 million, an 11% increase from $7.6 million in Q1 2024 [7] - Gross margin improved to 60%, up from 59% in Q1 2024 [9] - Cash and cash equivalents decreased to $12.4 million from $20.1 million at the end of 2024 [10] Business Line Data and Key Metrics Changes - Biologics and Drug Delivery revenue increased by 9% to $4.7 million, driven by a $1.2 million increase in product revenue [7][8] - Neurosurgery Navigation revenue grew 70% to $3.3 million, attributed to higher sales of new product offerings [8] - Capital Equipment and Software revenue decreased 63% to $500,000 due to fewer new placements of navigation and laser units [9] Market Data and Key Metrics Changes - The company activated two new sites in Q1 2025, expanding its installed base [19][50] - The single-use consumables business saw a growth rate of 104%, driven by increased orders from biopharma partners [13] Company Strategy and Development Direction - The company aims to extend its lead in cell and gene therapy through a comprehensive drug delivery ecosystem [4] - Plans to evolve the product portfolio to enhance hospital efficiency and throughput [5] - The company is focused on expanding its global installed base and generating scale for novel treatments [5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential for additional cell and gene therapy platforms to gain regulatory approval within two years [15] - The recent partnership with Overland Capital provides the company with foundational funding to execute its strategy [6][12] - Management anticipates that revenue growth will outpace expense growth for the full year [11][56] Other Important Information - The company has implemented a new subscription program called Pathfinder, allowing hospitals to access technology through an annual fee [21] - The Pathfinder program will smooth out capital revenue recognition over time [22] Q&A Session Summary Question: Opportunities with Incremental Capital - Management sees opportunities to accelerate hiring and expand preclinical resources in response to pharma partners' requests [29] Question: Neuro Franchise Growth Expectations - Management believes the neuro franchise can grow significantly more than 20% throughout the year, with potential upside based on product adoption [33] Question: MRI vs. OR Procedure Mix - Management anticipates a shift towards more procedures being performed in the operating room, especially as new drug therapies are introduced [39] Question: GLP Certification Timeline - Management expects to achieve GLP certification by the end of the year, with pent-up demand from pharma partners for studies once certified [42][44]

Bio-Techne (TECH) 2025 Conference May 13, 2025 01:40 PM ET Speaker0 Fireside Chat. I'm joined by Kim Kelderman, Chief Executive Officer and Jim Hipple, Chief Financial Officer. Gentlemen, thanks for being here. Thanks for having us. Format is going to be a fireside chat, and then we'll open up to the audience. If there's any questions, just raise your hand and we can squeeze you in as well. I guess just to kick things off, you reported fiscal 3Q results recently, solid results, especially considering some o ...

OXB to Present at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) Oxford, UK – 9 May 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces its participation in the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place from 13–17 May 2025 at the Ernest N. Morial Convention Center in New Orleans, Louisiana. The Company will exhibit at Booth #1611, where delegates can meet OXB’s team of viral v ...